
Balchem rose 12.7% from $156.11 to $175.99, ahead of the S&P 500's +9.8%. Its worst day was Apr 30 (−6.8%), and its low came Dec 8 at $147.36.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Balchem closed at its lowest level of the year, 5.6% below where the year started.
−2.1% · S&P 500 −0.3%
Balchem shares rose 3.8%, while the S&P 500 fell 0.0%.
+3.8% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
EPS of $1.31 beat the $1.28 estimate on $263.6M revenue (est. $261.4M).
−2.1% · S&P 500 +0.7%
Balchem closed at its highest level of the year, 17.4% above where the year started.
+1.0% · S&P 500 +0.1%
EPS of $1.33 beat the $1.33 estimate on $270.7M revenue (est. $266.5M).
−6.8%, the year's worst day · S&P 500 +1.0%
EPS of $1.49 beat the $1.42 estimate on $284.0M revenue (est. $268.5M).
+3.0% · S&P 500 +0.7%
EPS of $1.57 beat the $1.53 estimate on $290.7M revenue (est. $289.2M).
+2.2% · S&P 500 −0.5%
Balchem shares rose 4.0%, while the S&P 500 rose 1.7%.
+4.0% · S&P 500 +1.7%
Where it ended: a close of $175.99 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 19, 2027 (EPS est. $1.47, revenue est. $286.9M).
As of the Nov 9, 2026 close
Replay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BCPC and SPY from Benzinga historical bars. Not investment advice.